Focus on Lymphoma
Speaker: John Leonard, MD, and Jonathan Friedberg, MD, MMSc
John P. Leonard, MD, and Jonathan W. Friedberg, MD, discuss exciting updates in lymphoma, including newly approved drugs (e.g., obinutuzumab for chronic lymphocytic leukemia) and new data that may have practice-changing implications for various lymphoma subtypes. Lymphoma is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM). MHM is structured in a “How I Treat” format, which focuses not only on what the data show but on how to apply the data to optimally treat patients. The 2017 ASH Meeting on Hematologic Malignancies will also feature a talk that focuses on which tests to run to diagnose and follow patients across the non-Hodgkin lymphoma spectrum.
Focus on MPN
Speaker: Ruben Mesa, MD
Ruben A. Mesa, MD, discusses exciting updates in myeloproliferative neoplasms (MPN), including new JAK-2 inhibitors that might influence treatment and the emergence of precision medicine. MPN is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM), a practical and practice-focused meeting that offers an ideal learning experience for physicians who treat myeloproliferative neoplasms. The meeting’s expert speakers discuss challenging patient cases, present new data, and provide insight into how physicians can apply new treatments to patients the very next day.